Abstract
Branch retinal vein occlusion (BRVO) was first described in 1855 as a “retinal apoplexy” by Liebreich (Liebreich 1855) and as thrombotic in nature by von Michel in 1878 (von Michel 1878).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
BVOS Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Branch vein occlusion study group. Am J Ophthalmol. 1984;98:271–82.
BVOS Group. Argon scatter laser photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. The branch vein occlusion study group. Arch Ophthalmol. 1986;104:34–41.
Campochiaro PA, Hafiz G, Mir TA, et al. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology. 2015;122:1426–37.
Campochiaro PA, Heier JS, Feiner L et al. for BRAVO investigators. Ranibizumab for macular edema following BRVO: six-month primary end points of a phase III study. Ophthalmology. 2010;117:1102–1112. e.1101.
Campochiaro PA, Sophie R, Pearlman J, et al. Long term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121:209–19.
Cheung N, Klein R, Wang JJ, et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci. 2008;49:4297–302.
Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology. 1999;106(11):2054–62.
Clark WL, Boyer DS, Heier JS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 52-week results of the VIBRANT study. Ophthalmology. 2016;123:330–6.
Feist RM, Ticho BH, Shapiro MJ, Farber M. Branch retinal vein occlusion and quadrantic variation in arteriovenous crossings. Am J Ophthalmol. 1992;113:664–8.
Haller JA, Bandello F, Belfort R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion 12 month study results. Ophthalmology. 2011;118:2453–60.
Hayreh S. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005;24:493–519.
Hayreh SS, Rojas P, Podhajsky P, et al. Ocular neovascularization with retinal vascular occlusion- III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology. 1983;90(5):488–506.
Hayreh SS, Zimmerman B, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117:429–41.
Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802–9.
Klein R, Moss SE, Meuer SM, Klein BE. The 15 year cumulative incidence of retinal vein occlusion: the beaver dam eye study. Arch Ophthalmol. 2008;126(4):513–8.
Lam HD, Lahey JM, Kearney JJ, et al. Young patients with branch retinal vein occlusion: a review of 60 cases. Retina. 2010;30(9):1520–3.
Liebreich R. Ophthalmoskopische Notizen: Ueber die Farbe des Augengrundes. Albrech Von Graefes Arch Ophthalmol. 1855;1:333–43.
Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains eye study. Arch Ophthalmol. 1996;114(10):1242–7.
Rogers S, McIntosh RL, Cheung N, et al. Pooled data from population studies from the United States, Europe, Asia and Australia. Ophthalmology. 2010a;117:313–9.
Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence based systemic review. Ophthalmology. 2010b;117(6):1094–1101.e5.
Rush RB, Simunovic MP, Aragon AV 2nd, Ysasaga JE. Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina. 2014;45:212–6.
Scott IU, Ip MS, Van Veldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusions: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115–28.
Tadayoni R, Waldstein SM, Boscia F, et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion – 24month results of the BRIGHTER study. Ophthalmology. 2017;124(12):1778–87.
Tan MH, McAllister IL, Gillies ME, et al. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol. 2014;157:237–247.e1.
Trope GELG, McArdle BM, Douglas JT, et al. Abnormal blood viscosity and hemostasis in long-standing retinal vein occlusion. Br J Ophthalmol. 1983;67(3):137–42.
Von Michel J. Die spontane Thrombose der Vena Centralis des Opticus. Graefes Arch Ophthalmol. 1878;24:37–70.
Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol. 1990;109(3):298–302.
Zhao JSS, Sperduto RD, Chew EY, Remalay NA. Arteriovenous crossing patterns in branch retinal vein occlusion. Ophthalmology. 1993;100(3):423–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Leong, B.C.S., Freund, K.B. (2020). Branch Retinal Vein Occlusion. In: Sheyman, A., Fawzi, A.A. (eds) Retinal Vascular Disease. Retina Atlas. Springer, Singapore. https://doi.org/10.1007/978-981-15-4075-2_5
Download citation
DOI: https://doi.org/10.1007/978-981-15-4075-2_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-4074-5
Online ISBN: 978-981-15-4075-2
eBook Packages: MedicineMedicine (R0)